OncoMRD: Enabling detection superiority of residual disease through gene expression profiling
OncoDxRx announced a new cfmRNA-based MRD assay creatively named OncoMRD (OncoDxRxs monitoring residual disease), which the company said is based on its in-service patient-derived gene expression signature.
- (1888PressRelease) July 01, 2024 - OncoMRD (OncoDxRxs monitoring residual disease) is a flagship program for OncoDxRx. It addresses one of the key priorities in precision oncology: upgrading the molecular residual disease capabilities for solid tumors.
The OncoMRD technology aims to transform clinicians therapeutic efficacy monitoring capabilities to benefit patients. Better informed and more sensitive, all the procedures developed within the framework of OncoMRD are also fully connected and share laboratory testing information instantaneously.
The challenge of a molecular residual disease system is to deliver in an immediately understandable and exploitable form, in guaranteed short period of time, the information useful to the oncologist who will decide and lead the therapeutic action.
Outperforming the ctDNA-based systems, OncoMRD covers the needs of oncologists. It allows, for the first time, the capture of information, from tumor and non-tumor microenvironment, necessary for the monitoring of tumor response following treatment, and the quantitative interpretation of the presence or absence of the residual disease; all from a tube of blood.
OncoMRD now offers clinicians an effective test designed for high-need patients, which is easy to implement, quick turnaround, low cost and robust. It can automate many tasks and provides unparalleled fluidity of integration into different laboratory workflows.
With OncoMRD, oncologists now have a novel residual disease monitoring system that gives them real tactical superiority. OncoMRD is a true hit-and-tell tool, giving them an operational advantage. It enables the recognition of trusted situations, which makes it possible to gain the upper hand over the tumor clones within the patient.
OncoMRD allows the realization, in reflex time, of a complete post-treatment situation, residual gene activity information of the tumor. This information is provided via a customized report delivered within 5 days.
OncoMRD further allows the networking of all resources to make laboratory detection systems communicate with digital data analytics systems. It offers native interoperability with other systems at higher echelons and with reporting and billing systems.
OncoMRD gives a new dimension to residual disease monitoring in the digitized laboratory space.
Leveraging its expertise in therapy-critical systems and high-sensitivity technologies, and its ability to implement complex solutions in heterogeneous clinical environments, the OncoDxRx agile approach hardens innovative technologies to meet patient needs.
The medical community was convinced by this approach, which makes it possible to offer modernized ergonomics and scalable patient-centered functionalities within a controlled budget. The use of exclusive technologies will reduce the cost of OncoMRD and will dominate the market. The partnership program allows partner laboratories to take into account new needs and integrate them as they arise.
Developed to adapt to the constraints of laboratories, OncoMRD will be used today and tomorrow by our partner laboratories. With OncoMRD technology, OncoDxRx and its partners are fully entering the era of the data-centric and info-operated oncology battlefield.
The OncoMRD system delivers immediately understandable information thats useful to oncologists making clinical decision. OncoMRD also makes it possible, through a user interface adapted to operational needs, to automate tasks and to make them transparent for the user. The simple learning curve, fast training and maintenance of skills thus improve the usability of the system and contribute to the enhancement of the operational efficiency of the clinical laboratories.
OncoDxRx has started deploying OncoMRD in beta testing phase, working with our partners on regular updates for continuous improvement.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam